A Study to Assess the Safety and Pharmacokinetics of INCB123667 When Administered Orally to Adult Participants With Moderate or Severe Hepatic Impairment
NCT07559474 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2026-04-30
Summary
This study will be conducted to assess the safety and pharmacokinetics of INCB123667 when administered orally to adult participants with moderate or severe hepatic impairment.
Conditions
- Hepatic Insufficiency
- Liver Diseases
Interventions
- DRUG
-
INCB123667
single dose administered orally
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Incyte Medical Monitor · Incyte Corporation
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-05-15
- Primary Completion
- 2027-04-13
- Completion
- 2027-04-13
- FDA Drug
- Yes
More Related Trials
-
Single-Dose PK and Safety Study of GBT440 in Subjects With Hepatic Impairment
NCT03114540 ·Status: COMPLETED ·Phase: PHASE1
-
PK Study in Subjects With Severe Hepatic Impairment
NCT03664544 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of the Pharmacokinetics and Safety of LY3537031 in Participants With Normal Liver Function and With Mild, Moderate, or Severe Liver Impairment
NCT07165002 ·Status: RECRUITING ·Phase: PHASE1
-
A Study on The Effect of Hepatic Impairment on The Pharmacokinetics of RO4917838
NCT01356550 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Study of MCI-186 in Subjects With Mild or Moderate Hepatic Impairment
NCT03289234 ·Status: COMPLETED ·Phase: PHASE1
-
PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers
NCT02121860 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment
NCT04587622 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986036 in Participants With Normal Liver Function and Participants With Moderate and Severe Liver Impairment
NCT04634149 ·Status: COMPLETED ·Phase: PHASE1
-
Single-Dose Pharmacokinetics of MK-3866 in Participants With Hepatic Impairment (MK-3866-006)
NCT03295266 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic Insufficiency
NCT01916993 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Test How BI 1015550 is Taken up in the Blood of People With and Without Liver Problems
NCT05661344 ·Status: COMPLETED ·Phase: PHASE1
-
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Hepatic Function and Hepatic Impairment.
NCT04831944 ·Status: COMPLETED ·Phase: PHASE1
-
A Safety and Tolerability Study of CP-690,550 in Subjects With Hepatic Impairment and Normal Hepatic Function
NCT00969813 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction
NCT05224609 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001
NCT06619054 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
NCT05857644 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Pharmacokinetics of Zanubrutinib (BGB-3111) in Healthy Subjects and Those With Impaired Liver Function
NCT03465059 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With and Without Reduced Liver Function
NCT07269301 ·Status: RECRUITING ·Phase: PHASE1
-
A Research Study Looking at How a Single Dose of the Study Medicine NNC0194-0499 Behaves in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
NCT05917938 ·Status: COMPLETED ·Phase: PHASE1
-
Ulonivirine (MK-8507) in Participants With Mild or Moderate Hepatic Impairment (MK-8507-014)
NCT05093972 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Research Study on Etavopivat in Participants With and Without Liver Disease
NCT06336018 ·Status: COMPLETED ·Phase: PHASE1
-
Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543
NCT05467722 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects
NCT03824678 ·Status: COMPLETED ·Phase: PHASE1
-
Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects
NCT02231450 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic Impairment
NCT05517525 ·Status: COMPLETED ·Phase: PHASE1